FDA approves HBV vaccine Heplisav-B for adults

14:05 EST 10 Nov 2017 | Healio

Dynavax announced that the FDA approved Heplisav-B, a recombinant hepatitis B vaccine, for all known subtypes of HBV in adults aged 18 years or older, according to a press release.
William Schaffner Robert Janssen
“Once physicians and public health institutions become aware of Heplisav-B, it will be an attractive option to use for all those individuals who are indicated to receive hepatitis B vaccines as adults who haven’t been vaccinated as children,” William Schaffner, MD, professor of preventive medicine at the Vanderbilt University Medical Center, and a public health

Original Article: FDA approves HBV vaccine Heplisav-B for adults


More From BioPortfolio on "FDA approves HBV vaccine Heplisav-B for adults"

Quick Search


Relevant Topic

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...